Genetically modified megakaryocytes, modified platelets and methods for producing the same
By using CRISPR-Cas family proteins and gRNA complexes for genome editing in megakaryocytes, the HLA or β2-microglobulin genes are solved, and the problems of low efficiency and high cost of gene editing in the prior art are achieved, and high efficiency and low efficiency are achieved Antigenic platelet preparation.
Patent Information
- Application Number
- CN202180008211.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-02-28
- Filing Date
- 2021-03-01
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-03-01
AI Technical Summary
The prior art is difficult to efficiently perform genome editing in megakaryocytes by methods other than viral vectors, and the use of lentiviral vectors has off-target mutations, antigenicity, and adverse effects on genomic function, and the process is complex and costly.
CRISPR-Cas family proteins and guide RNA (gRNA) complexes were used to introduce megakaryocytes through electroporation or liposome transfection, which effectively destroyed the HLA-A, HLA-B, HLA-C or β2-microglobulin genes. Generates defective megakaryocytes and platelets.
Efficient megakaryocyte genome editing is achieved, reducing HLA antigen-mediated immune rejection, simplifying the process, reducing costs, and improving the transplantability and production efficiency of platelet preparations.
Smart Images

Figure BDA0003732637300000181 
Figure BDA0003732637300000201 
Figure BDA0003732637300000221
Abstract
Description
Technical Field
[0001] The present invention relates to genetically modified megakaryocytes, modified platelets, and methods for producing the same. This application claims priority based on Japanese Patent Application No. 2020-034255 filed in Japan on February 28, 2020, the contents of which are incorporated herein by reference. Background Art
[0002] Platelets are a type of cell produced from the cytoplasm of megakaryocytes in the bone marrow. Platelets play a key role in thrombosis, and when the blood vessel wall is damaged, they aggregate and plug the wound, thus playing a role in hemostasis.
[0003] Platelet transfusion is performed for the purpose of achieving hemostasis or prevention of bleeding by supplementing platelet components in cases of severe bleeding or conditions where bleeding is expected due to a decrease in the number of platelets or abnormalities in their function.
[0004] However, it is known that in patients with platelet refractoriness, antibodies against class I human leukocyte antigen (HLA) are abnormally produced, resulting in the destruction of transplanted platelets. In view of this, if HLA-deficient platelets can be produced, it is expected that transplantation can be performed on patients with platelet refractoriness who have antibodies against class I HLA.
[0005] In recent years, the CRISPR-Cas9 system, one of the acquired immune systems of prokaryotes, is being widely used in genome editing technologies such as gene disruption (knockout). This is a technology that uses this system to induce double-stranded DNA breaks (DSBs) at the desired site of genomic DNA, and then uses the repair mechanism of the host cell to cause deletions and insertions. In addition, it is known that Cas family proteins other than Cas9 can also be used for genome editing.
[0006] As a method for making HLA protein-deficient platelets, since platelets do not have a genome, it is considered to destroy the HLA gene by genome editing in megakaryocytes as the previous stage, and obtain the above-mentioned platelets from HLA protein-deficient megakaryocytes. However, as described in Non-Patent Literature 1, it is known that it is difficult to express foreign genes in megakaryocytes by methods other than viral vectors. Megakaryocytes are giant cells with a diameter of 35 to 160 μm, and part of the cell membrane stretches and is broken by the severe shear stress caused by turbulence, thereby producing platelets. That is, the cell membrane of megakaryocytes is soft and tough compared to other cells, and it is believed that the specificity of the membrane structure will make it difficult to introduce genes from the outside.
[0007] In addition, Non-Patent Document 2 describes that genome editing could not be performed in megakaryocytes obtained by differentiation induction of iPS cells. Therefore, Non-Patent Document 2 describes that megakaryocytes are reprogrammed back to iPS cells, and then genome-edited and induced to differentiate into megakaryocytes again.
[0008] In addition, Non-Patent Document 3 describes that Cas9 and gRNA are introduced into megakaryocytes using a lentiviral vector, thereby performing genome editing of megakaryocytes.
[0009] Prior art literature
[0010] Non-patent literature
[0011] Non-patent document 1: Isakari Y., et al., Efficient gene expression in megakaryocytic cell line using nucleofection, Int J Pharm., 338(1-2), 157-64, 2007.
[0012] Non-patent literature 2: Seo H., et al., A beta1-tubulin-based megakaryocytematuration reporter system identifies novel drugs that promote platelet production, Blood Adv., 2(17), 2262-2272, 2018.
[0013] Non-patent document 3: Kahr WH, et al., Loss of the Arp2 / 3complex componentARPC1B causes platelet abnormalities and predisposes to inflammatory disease, Nat Commun., 8: 14816, 2017. Summary of the invention
[0014] Problems to be solved by the invention
[0015] However, in the method of non-patent literature 2, a large amount of labor and time are required in the initialization induction of iPS cells and the differentiation to megakaryocytes again, and the efficiency is poor. In addition, in the method of non-patent literature 3, since the introduced gene is inserted into the genomic DNA of megakaryocytes and cannot be removed, there is a risk that the expression of exogenous genes becomes a new antigen and the risk of adversely affecting the function of endogenous genes. In more detail, in the genome editing using a lentiviral vector, Cas9 gene, sgRNA, etc. are inserted into the genome. Therefore, the megakaryocytes obtained are expected to have the risk of off-target mutation introduction, antigenicity caused by Cas9 protein expression, and the influence of endogenous genome on gene function (activation of oncogenes, etc.), becoming megakaryocytes that are not suitable for clinical application. In addition, regarding the use of lentivirus, there are problems such as limited implementation facilities and increased manufacturing costs, and other simpler methods are needed.
[0016] Based on such background, an object of the present invention is to provide a technology for producing genetically modified megakaryocytes and modified platelets.
[0017] Methods used to solve problems
[0018] The present invention includes the following aspects.
[0019] [1] A method for producing genetically modified megakaryocytes, comprising the step of introducing a CRISPR-associated (Cas) family protein and a guide RNA (gRNA) into the megakaryocytes to modify a target gene, wherein the Cas family protein to be introduced into the megakaryocytes and the gRNA form a complex in advance.
[0020] [2] The production method according to [1], wherein the introduction of the above-mentioned Cas family protein and the above-mentioned gRNA is carried out by a liposome transfection method or an electroporation method suitable for protein introduction.
[0021] [3] The production method according to [1] or [2], wherein the introduction of the above-mentioned Cas family protein and the above-mentioned gRNA is carried out by electroporation.
[0022] [4] The production method according to any one of [1] to [3], wherein the target gene is (i) human leukocyte antigen (HLA)-A, HLA-B and HLA-C genes, or (ii) β2-microglobulin (B2M) gene, and the modification is the disruption of the target gene.
[0023] [5] The production method according to any one of [1] to [4], wherein the megakaryocytes are megakaryocytes obtained by differentiating pluripotent stem cells.
[0024] [6] A genetically modified megakaryocyte, wherein (i) HLA-A, HLA-B and HLA-C genes, or (ii) B2M gene has been disrupted.
[0025] [7] A method for producing modified platelets, comprising: a step of introducing a Cas family protein and a gRNA into megakaryocytes to modify a target gene, thereby obtaining genetically modified megakaryocytes; and a step of producing platelets from the genetically modified megakaryocytes to obtain modified platelets, wherein in the step of obtaining the genetically modified megakaryocytes, the Cas family protein to be introduced into the megakaryocytes and the gRNA pre-form a complex.
[0026] [8] The production method according to [7], wherein the introduction of the above-mentioned Cas family protein and the above-mentioned gRNA is carried out by liposome transfection or electroporation suitable for protein introduction.
[0027] [9] The production method according to [7] or [8], wherein the introduction of the above-mentioned Cas family protein and the above-mentioned gRNA is carried out by electroporation.
[0028]
[10] The production method according to any one of [7] to [9], wherein the megakaryocytes are megakaryocytes obtained by differentiating pluripotent stem cells.
[0029]
[11] The production method according to any one of [7] to
[10] , wherein the target gene is (i) HLA-A, HLA-B and HLA-C gene, or (ii) B2M gene, and the modification is the disruption of the target gene.
[0030]
[12] An HLA-deficient platelet, wherein HLA-A protein, HLA-B protein and HLA-C protein are deficient.
[0031]
[13] The HLA-deficient platelet according to
[12] , which is produced using the production method described in
[11] .
[0032]
[14] A method for producing genetically modified megakaryocytes, comprising the step of introducing a Cas family protein and a gRNA into the megakaryocytes to modify a target gene, wherein the introduction of the Cas family protein and the gRNA is performed by electroporation.
[0033]
[15] The production method according to
[14] , wherein the megakaryocytes are megakaryocytes obtained by differentiating pluripotent stem cells.
[0034]
[16] The production method according to
[14] or
[15] , wherein electroporation is performed using 0.1 to 1 pmol of Cas family protein and 0.1 to 1 pmol of gRNA per 1000 megakaryocytes.
[0035]
[17] The production method according to any one of
[14] to
[16] , wherein the target gene is (i) human leukocyte antigen (HLA)-A, HLA-B and HLA-C genes, or (ii) β2-microglobulin (B2M) gene, and the modification is the destruction of the target gene.
[0036]
[18] A genetically modified megakaryocyte produced by the production method described in
[17] , wherein (i) HLA-A, HLA-B and HLA-C genes, or (ii) B2M gene has been disrupted.
[0037]
[19] A method for producing modified platelets, comprising: a step of introducing a Cas family protein and a gRNA into megakaryocytes by electroporation to modify a target gene, thereby obtaining genetically modified megakaryocytes; and a step of producing platelets from the genetically modified megakaryocytes to obtain modified platelets.
[0038] The present invention may also include the following aspects.
[0039] [P1] A method for producing genetically modified megakaryocytes, comprising the step of introducing a CRISPR-associated (Cas) family protein and a guide RNA (gRNA) into megakaryocytes to modify a target gene.
[0040] [P2] The method for producing genetically modified megakaryocytes according to [P1], wherein the introduction of the Cas family protein and gRNA is carried out by electroporation.
[0041] [P3] A method for producing genetically modified megakaryocytes according to [P1] or [P2], wherein the target gene is (i) human leukocyte antigen (HLA)-A, HLA-B and HLA-C genes, or (ii) β2-microglobulin (B2M) gene, and the modification is the destruction of the target gene.
[0042] [P4] The method for producing genetically modified megakaryocytes according to any one of [P1] to [P3], wherein the megakaryocytes are megakaryocytes obtained by differentiating pluripotent stem cells.
[0043] [P5] A genetically modified megakaryocyte, wherein (i) HLA-A, HLA-B and HLA-C genes, or (ii) B2M gene has been disrupted.
[0044] [P6] A method for producing modified platelets, comprising: a step of introducing Cas family proteins and gRNA into megakaryocytes to modify target genes, thereby obtaining genetically modified megakaryocytes; and a step of producing platelets from the genetically modified megakaryocytes to obtain modified platelets.
[0045] [P7] The method for producing modified platelets according to [P6], wherein the introduction of the above-mentioned Cas family protein and gRNA is carried out by electroporation.
[0046] [P8] A method for producing modified platelets according to [P6] or [P7], wherein the target gene is (i) HLA-A, HLA-B and HLA-C gene, or (ii) B2M gene, and the modification is the destruction of the target gene.
[0047] [P9] The method for producing modified platelets according to any one of [P6] to [P8], wherein the megakaryocytes are megakaryocytes obtained by differentiating pluripotent stem cells.
[0048] [P10] An HLA-deficient platelet, wherein HLA-A protein, HLA-B protein and HLA-C protein are deficient.
[0049] Effects of the Invention
[0050] According to the present invention, a technique for producing genetically modified megakaryocytes and modified platelets can be provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 Graphs showing the results of flow cytometry analysis in Experimental Example 1.
[0052] Figure 2 Graphs showing the results of flow cytometry analysis in Experimental Example 2.
[0053] Figure 3 (a) is a diagram showing gate settings for flow cytometry analysis in Experimental Example 3. (b) is a diagram showing the results of flow cytometry analysis in Experimental Example 3.
[0054] Figure 4 (a) and (b) are graphs showing the results of flow cytometry analysis in Experimental Example 4.
[0055] Figure 5 (a) and (b) are graphs showing the results of flow cytometry analysis in Experimental Example 5.
[0056] Figure 6 (a) and (b) are graphs showing the results of flow cytometry analysis in Experimental Example 5.
[0057] Figure 7 (a) and (b) are graphs showing the results of flow cytometry analysis in Experimental Example 5.
[0058] Figure 8 (a) and (b) are graphs showing the results of flow cytometry analysis in Experimental Example 5. DETAILED DESCRIPTION
[0059] [Method for producing genetically modified megakaryocytes]
[0060] In one embodiment, the present invention provides a method for producing genetically modified megakaryocytes, comprising the step of introducing Cas family proteins and gRNA into megakaryocytes to modify the target gene. In the production method of this embodiment, the Cas family protein to be introduced into the megakaryocyte and the gRNA form a complex in advance.
[0061] Generally, compared with directly introducing protein into cells, when an expression vector is introduced into cells and expressed in cells, the amount of protein in cells will be greater. Therefore, it is common knowledge for those skilled in the art to introduce Cas family proteins and gRNA into cells in the form of expression vectors in order to efficiently perform genome editing. In contrast, as described in the embodiments described later, the inventors have made it clear that genome editing can be performed by introducing a complex of Cas family proteins and gRNA into megakaryocytes, and the target gene can be efficiently transformed.
[0062] In addition, as described in the examples described below, compared with the case of introducing plasmid DNA for genome editing, by introducing a complex of Cas family protein and gRNA, genetic modification can be performed efficiently at an early stage.
[0063] (Megakaryocyte)
[0064] In the manufacturing method of the present embodiment, megakaryocytes can be from humans or non-human animals, and can be appropriately selected according to the purpose. It can be megakaryocytes collected from humans or non-human animals, it can be megakaryocytes obtained by differentiation induction of hematopoietic stem cells collected from humans or non-human animals, it can be megakaryocytes obtained by differentiation induction of pluripotent stem cells from humans or non-human animals. As pluripotent stem cells, embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells) etc. can be listed.
[0065] Megakaryocytes may also be genetically manipulated. For example, megakaryocytes immortalized by forced expression of the BMI1 gene, c-MYC gene, and BCL-xL gene in the presence of doxycycline may be used. Such megakaryocytes may be expanded and cultured in the presence of doxycycline, and platelets may be produced by removing doxycycline.
[0066] (Cas family proteins)
[0067] As Cas family proteins, for example, Cas9, Cpf1 (also known as Cas12a), C2C1 (also known as Cas12b), C2C2 (also known as Cas13a), CasX, CasY, Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas10, etc. CRISPR-Cas systems can be divided into Class I and Class II. In the past, Class II systems with Cas9 as the core were generally used, but now Class I systems can also be used.
[0068] Cas family proteins can be substances in which these proteins have been transformed. For example, it can be a nickase-modified nuclease in which one of the two wild-type nuclease domains is transformed into an inactive type, or it can be dCas9 in which both are transformed into inactive types. Alternatively, it can be Cas9-HF, HiFi-Cas9, eCas9, etc. with improved target specificity. In addition, it can be a substance fused with other proteins (enzymes, etc.) on these Cas9.
[0069] Examples of Cas9 proteins include proteins derived from Streptococcus pyogenes, Staphylococcus aureus, Streptococcus thermophilus, Bacillus stearothermophilus, etc. Examples of Cpf1 proteins include proteins derived from Acidaminococcus, Lachnospira, Chlamydomonas, Francisella novicida, etc.
[0070] (gRNA)
[0071] The gRNA used is the gRNA corresponding to the Cas family protein used. The gRNA is used to determine the position on the genomic DNA where the Cas family protein induces double-stranded DNA breaks, that is, the target gene to be modified.
[0072] In this specification, the target base sequence of gRNA refers to the base sequence on the single-stranded DNA that forms a complementary chain with the DNA hybridized with the spacer base sequence of gRNA. The spacer sequence of gRNA is complementary to the antisense strand of the target sequence. Therefore, the sequence identity of the spacer base sequence of gRNA and the base sequence of the sense strand of the target sequence is high, and the spacer base sequence of gRNA is substantially complementary to the base sequence of the antisense strand of the target sequence.
[0073] The gRNA can be a complex of CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), or a single gRNA (sgRNA) composed of tracrRNA and crRNA.
[0074] As a method for preparing gRNA in the form of RNA, there can be listed: a method of adding a promoter such as T7 upstream of a nucleic acid fragment encoding gRNA to prepare a construct and synthesizing it by an in vitro transcription reaction; a method of chemical synthesis, etc. In the case of chemically synthesizing gRNA, chemically modified RNA can be used.
[0075] For example, when the base sequence after removing the PAM sequence from the target base sequence is "5'-NNNNNNNNNNNNNNNNNNNN-3'" (sequence number 1), the base sequence of the sgRNA that specifically cuts the target base sequence can be set to "5'-NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3'" (sequence number 2).
[0076] As long as the base sequence of the sgRNA functions as an sgRNA, it may also have a mutation relative to the base sequence recorded in SEQ ID NO: 2. More specifically, it may be a base sequence in which one or several bases are deleted, substituted, or added to the base sequence recorded in SEQ ID NO: 2. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases.
[0077] When the gRNA is a complex of crRNA and tracrRNA, the base sequences of crRNA and tracrRNA can be set to the following base sequences.
[0078] First, the base sequence of the PAM sequence removed from the target base sequence is used as the spacer base sequence. Then, the base sequence of the scaffold sequence is connected to the 3' end of the spacer base sequence as the base sequence of crRNA. For example, when the base sequence (spacer base sequence) of the PAM sequence removed from the target base sequence is "5'-NNNNNNNNNNNNNNNNNNNN-3'" (sequence number 1), the base sequence of crRNA can be set to "5'-NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGUUUUG-3'" (sequence number 3). In addition, the base sequence of tracrRNA can be set to, for example, "5'-CAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3'" (sequence number 4).
[0079] As long as the base sequence of crRNA functions as crRNA, it may have a mutation relative to the base sequence recorded in sequence number 3. More specifically, it may be a base sequence in which one or several bases are deleted, substituted or added in the base sequence recorded in sequence number 3. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases.
[0080] In addition, as long as the base sequence of tracrRNA functions as tracrRNA, it may be a base sequence in which one or several bases are deleted, substituted or added to the base sequence described in SEQ ID NO: 4. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases.
[0081] (Introduction of Cas family proteins and gRNA)
[0082] The method (transfection method) for introducing Cas family proteins and gRNA into megakaryocytes is not particularly limited, and examples thereof include liposome transfection, electroporation, microinjection, etc. In this specification, "transfection" refers to the introduction of nucleic acids and proteins into cells by methods other than viral infection. When transfection is performed, commercially available transfection reagents can be appropriately used.
[0083] As the transfection reagent, a reagent capable of introducing proteins into cells is preferred, for example, Lipofectamine CRISPRMAX (Thermo Fisher Scientific), Pro-DeliverIN CRISPR transfection reagent (OZ Biosciences), Avalanche(R)-CRISPR transfection reagent (EZ Biossytems), etc. can be used.
[0084] Alternatively, electroporation can be performed using equipment such as NEPA21 (Neppson Co., Ltd.), Neon (Thermo Fisher Scientific), 4D-Nucleofector (Lonza), and MaxCyte System (MaxCyte).
[0085] Cas family proteins and gRNA are preferably introduced into megakaryocytes in the form of a complex. Cas family proteins and gRNA can form a complex by mixing. Cas family proteins and gRNA can be mixed before being introduced into megakaryocytes, incubated for several minutes (e.g., 1 to 10 minutes, 1 to 7 minutes, 1 to 5 minutes, 3 to 5 minutes, about 5 minutes), for example, incubated for about 5 minutes, thereby promoting complex formation.
[0086] (Target gene)
[0087] In the manufacturing method of this embodiment, the base sequence on the target gene is set as the target base sequence of gRNA. In the manufacturing method of this embodiment, the target gene can be a combination of (i) HLA-A gene, HLA-B gene and HLA-C gene. Alternatively, the target gene can be (ii) B2M gene. In addition, the "modified target gene" can be a destroyed target gene.
[0088] Here, disruption of the target gene refers to the introduction of deletions or insertions into the cleavage site of the target gene caused by the complex of the Cas family protein and the gRNA, resulting in frameshifts, introduction of stop codons, large-scale deletions, etc., which make it impossible to express functional proteins from the target gene.
[0089] The most important role in cells distinguishing between self and non-self is played by cell surface proteins called HLA (Human Leukocyte Antigen) or Major Histocompatibility Complex (MHC).
[0090] HLA can be divided into class I and class II. Class I HLA proteins are expressed in almost all types of cells in the body. Class I HLA proteins form heterodimers with β2-microglobulin (B2M) and are expressed on the cell surface. They have the function of presenting peptides to CD8-positive cell-killing T cells and inducing activation. The presented antigenic peptides are endogenous and are mostly 8 to 10 amino acids in length.
[0091] Class I HLA includes six genes: HLA-A gene, HLA-B gene, HLA-C gene, HLA-E gene, HLA-F gene, and HLA-G gene. In addition, many pseudogenes (HLA-H, HLA-J, HLA-K, HLA-L, HLA-P, HLA-T, HLA-U, HLA-V, HLA-W, HLA-X, HLA-Y, etc.) are also known. Among these, the three genes, HLA-A gene, HLA-B gene, and HLA-C gene, have the largest sequence diversity among individuals, and play a major role in identifying self and non-self in transplant immunity.
[0092] Class II HLA proteins are mainly expressed in immune cells such as macrophages, dendritic cells, activated T cells, and B cells. The α and β chains of class II HLA proteins form heterodimers, which are responsible for presenting peptides to CD4 helper T cells and inducing activation. The presented antigenic peptides are exogenous and mostly have a length of 15 to 24 amino acids.
[0093] HLA-DR (α chain: HLA-DRA, β chain: HLA-DRB), HLA-DQ (α chain: HLA-DQA1, β chain: HLA-DQB1), HLA-DP (α chain: HLA-DPA1 or HLA-DPA2, β chain: HLA-DPB1 or HLA-DPB2) are classified as class 2 HLA. In addition, the existence of various pseudogenes (HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB) is also known.
[0094] HLA-A protein, HLA-B protein and HLA-C protein have a high correlation with the rejection reaction when performing cell transplantation. Therefore, by manufacturing the genetically modified megakaryocytes that have destroyed the HLA-A gene, HLA-B gene and HLA-C gene of the megakaryocyte, and then producing platelets, the expression of the HLA protein on the platelet surface can be eliminated. Thus, it can be expected that the antigenicity during platelet transplantation can be reduced. In addition, for patients with antibodies to Class I HLA, transplantable platelet preparations can also be provided.
[0095] The target base sequence of the gRNA for destroying the HLA-A gene, HLA-B gene, and HLA-C gene of megakaryocytes determines the HLA alleles of the megakaryocytes and can be designed based on the determined base sequences of the HLA-A gene, HLA-B gene, and HLA-C gene.
[0096] The determination of HLA alleles can be performed by conventional methods such as PCR-rSSO (PCR-reverse Sequence Specific Oligonucleotide), PCR-SSP (Sequence specific primer), PCR-SBT (Sequence based typing), and next-generation sequencing, and can be performed using commercially available HLA typing kits, etc. In addition, as software for performing HLA typing from sequencing data of next-generation sequencing such as whole genome sequencing (WGS), exosome sequencing (WES), and RNA-seq, HLAreporter, HLA-PRG, hla-genotyper, PHLAT, Optitype, neXtype, Athlates, HLAforest, SOAP-HLA, HLAminer, seq2HLA, GATK HLA Caller, etc. are known, and these software can be used.
[0097] In addition, by deleting the B2M gene required for cell surface presentation of class I HLA proteins, it is also possible to eliminate the HLA-A protein, HLA-B protein, and HLA-C protein in megakaryocytes.
[0098] In addition, the "gene to be modified" is not limited to the disruption of the gene to be modified, and may also be the editing of the base sequence of the gene to be modified. As a result, a protein modified by the modified gene to be modified is expressed.
[0099] Specifically, the target gene can be modified by inducing double-stranded DNA breaks by specifically cleaving the target gene in the presence of donor DNA and inducing homologous recombination in the process of repairing the double-stranded DNA breaks.
[0100] As the donor DNA, a DNA having a sequence identity with the region before and after the double-stranded DNA break position containing the target gene and having a desired base sequence can be used. The donor DNA can be single-stranded DNA or double-stranded DNA. In addition, the donor DNA can be a DNA having a single base sequence or a mixture of DNAs having multiple base sequences.
[0101] Here, sequence identity means that more than 90% of the base sequence is identical between the donor DNA and the region containing the double-stranded cleavage position of the target gene. Preferably, more than 95% of the base sequence is identical between the donor DNA and the region containing the double-stranded cleavage position of the genomic DNA, and more preferably more than 99% of the base sequence is identical.
[0102] The donor DNA may be a single-stranded DNA of about 50 to 5000 base pairs, or a double-stranded DNA of about 50 to 5000 base pairs. When the donor DNA is a single-stranded DNA, the donor DNA may have sequence identity with either strand of the double strand of the genomic DNA.
[0103] Here, the sequence consistency of the query base sequence relative to the reference base sequence can be obtained, for example, as follows. First, the reference base sequence and the query base sequence are compared. Here, each base sequence may contain a gap to maximize the sequence consistency. Next, the number of bases that are consistent in the reference base sequence and the query base sequence is calculated, and the sequence consistency can be obtained according to the following formula (F1).
[0104] Sequence consistency (%) = number of consistent bases / total number of bases in the query sequence × 100 (F1)
[0105] [Genetically modified megakaryocytes]
[0106] In one embodiment, the present invention provides a genetically modified megakaryocyte, wherein (i) HLA-A, HLA-B and HLA-C genes, or (ii) B2M gene has been disrupted.
[0107] In the genetically modified megakaryocytes of the present embodiment, the expression of HLA protein is lost. In addition, HLA-deficient platelets can be produced by the megakaryocytes of the present embodiment. Therefore, according to the genetically modified megakaryocytes of the present embodiment, megakaryocytes or platelets that reduce HLA antigen-mediated immune rejection reactions during transplantation can be provided even in allogeneic transplantation. Platelet preparations will be inactivated within a few days even if they are made from donated blood, so the medical / industrial usefulness of cells that can maintain platelet production capacity and can be infinitely expanded and cultured, such as megakaryocytes from iPS cells, is very high.
[0108] In the past, megakaryocytes and platelets were produced only from iPS cells derived from HLA-matched donors. In contrast, according to the method of this embodiment, a single HLA-deficient platelet preparation can be transplanted to multiple recipients. As a result, the cost of platelet preparations can be drastically reduced compared to autologous transplantation.
[0109] [Method for producing modified platelets]
[0110] In one embodiment, the present invention provides a method for producing modified platelets, which comprises: a step of introducing Cas family proteins and gRNA into megakaryocytes to modify the target gene to obtain genetically modified megakaryocytes; and a step of producing platelets from the above-mentioned genetically modified megakaryocytes to obtain modified platelets.
[0111] The same as above is true about megakaryocytes, Cas family proteins, gRNA, target genes, etc. Megakaryocytes can be megakaryocytes obtained by differentiating pluripotent stem cells. By producing platelets from genetically modified megakaryocytes, modified platelets can be manufactured. Here, modified platelets refer to platelets in which the expression of proteins encoded by target genes has changed compared to wild-type platelets. The method for producing platelets from megakaryocytes is not particularly limited, and the method usually performed can be appropriately used.
[0112] In the manufacturing method of this embodiment, the introduction of Cas family proteins and gRNA into megakaryocytes is preferably performed by electroporation. As described in the embodiments described below, the inventors have made it clear that genome editing can be performed by introducing a complex of Cas family proteins and gRNA into megakaryocytes, which can more efficiently transform the target gene.
[0113] In the production method of this embodiment, the target gene is (i) HLA-A, HLA-B and HLA-C gene, or (ii) B2M gene, and the above modification can be the disruption of the above target gene. The same is true for the HLA-A gene, HLA-B gene, HLA-C gene and B2M gene.
[0114] By disrupting these genes, HLA-deficient megakaryocytes can be produced. In addition, HLA-deficient platelets can be produced from HLA-deficient megakaryocytes. That is, in this case, the platelets are transformed into HLA-deficient platelets.
[0115] In one embodiment, the present invention provides a method for producing low-antigenicity platelets, which comprises the following steps: (a) a step of inducing differentiation of pluripotent stem cells of human origin to produce immortalized megakaryocytes; (b) a step of using CRISPER-Cas gene modification technology to introduce a complex of Cas family proteins and gRNA into the above-mentioned immortalized megakaryocytes, thereby modifying or defecting two or more class I HLA proteins; (c) a step of proliferating immortalized megakaryocytes in which two or more class I HLA proteins have been modified or defective; and (d) a step of producing platelets from the proliferated megakaryocytes.
[0116] [HLA-deficient platelets]
[0117] In one embodiment, the present invention provides HLA-deficient platelets in which two or more class I HLA proteins are deficient. The two or more class I HLA proteins are preferably two or more proteins selected from the group consisting of HLA-A protein, HLA-B protein, and HLA-C protein, and more preferably HLA-A protein, HLA-B protein, and HLA-C protein.
[0118] In one embodiment, the present invention provides HLA-deficient platelets in which HLA-A protein, HLA-B protein and HLA-C protein are deficient. Alternatively, the present invention can also provide the above-mentioned HLA-deficient platelets in which HLA-A protein, HLA-B protein and / or HLA-C protein are deficient. As described above, in the HLA-deficient platelets of this embodiment, HLA protein is deficient. Therefore, even in the case of allogeneic transplantation, the immune rejection reaction mediated by HLA antigen can be reduced during transplantation. In addition, the HLA-deficient platelets of this embodiment can be mass-produced by the above-mentioned method.
[0119] [Other embodiments]
[0120] In one embodiment, the present invention provides a method for treating platelet-related diseases, comprising: introducing a complex of Cas family proteins and gRNA into megakaryocytes to modify (i) HLA-A, HLA-B and HLA-C genes, or (ii) B2M genes, to obtain HLA-deficient megakaryocytes; producing platelets from the above-mentioned HLA-deficient megakaryocytes to obtain HLA-deficient platelets; and administering an effective amount of the above-mentioned HLA-deficient platelets to a patient in need of treatment. Here, megakaryocytes, Cas family proteins, gRNA, target genes, etc. are the same as described above.
[0121] In the treatment method of this embodiment, the platelet-related disease refers to a condition in which bleeding is severe or predicted to occur due to a decrease in platelet count or abnormal function. In addition, the patient may be a patient with platelet transfusion ineffectiveness. In addition, the HLA-deficient platelets are preferably administered to the patient by intravenous drip.
[0122] Example
[0123] Next, the present invention will be described in further detail with reference to Examples, but the present invention is not limited to the following Examples.
[0124] [Experimental Example 1]
[0125] (HLA-A / B / C gene knockout in megakaryocytes)
[0126] Cas9 protein and sgRNA were introduced into megakaryocytes to knock out the HLA-A gene, HLA-B gene, and HLA-C gene (hereinafter sometimes referred to as "HLA-A / B / C gene").
[0127] As megakaryocytes, immortalized human megakaryocyte cell lines (imMKCL) in which BMI1 gene, c-MYC gene and BCL-xL gene are forcibly expressed in the presence of doxycycline (Crontech) were used (see Nakamura S., et al., Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells, Cell Stem Cell, 14(4), 535-548, 2014). The cells can be expanded and cultured in the presence of doxycycline, and platelets can be produced by removing doxycycline.
[0128] As Cas9 protein, a commercially available product (product name “TrueCut TMCas9 Protein v2”, catalog number “A36498”, Thermo Fisher Scientific).
[0129] As sgRNA, three types of sgRNA were used: a synthetic sgRNA targeting the HLA-A gene ("HLA-A-ex3g1", the target base sequence is shown in sequence number 5), a synthetic sgRNA targeting the HLA-B gene ("HLA-B-ex2g1", the target base sequence is shown in sequence number 6), and a synthetic sgRNA targeting the HLA-C gene ("HLA-C12:02-ex3g1", the target base sequence is shown in sequence number 7).
[0130] 15 μg of Cas9 protein, 1.25 μg of HLA-A-ex3g1, 1.25 μg of HLA-B-ex2g1, and 1.25 μg of HLA-C12:02-ex3g1 were mixed and incubated, and then introduced into 3×10 5 In the electroporation, the 4D-Nucleofector TM (LONZA CORPORATION) and P4 Primary Cell 4D-Nucleofector TM XKitS (catalog number "V4XP-4032", LONZA Corporation).
[0131] The electroporated megakaryocytes were added to a culture medium and cultured under the conditions of 37°C and 5% CO 2 . The composition of the culture medium is shown in Table 1 below.
[0132] [Table 1]
[0133]
[0134] Megakaryocytes were collected 3 days and 6 days after the start of culture and stained with FITC-labeled anti-HLA-A / B / C antibody (catalog number "555552", BD Biosciences). Then, flow cytometry analysis was performed using FACS Verse (BD Biosciences) to determine the proportion of cell populations in which all HLA-A / B / C genes were knocked out.
[0135] Figure 1 It is a figure which shows the result of flow cytometry analysis. Figure 1In the table, "wild type" indicates the results of wild type megakaryocytes, and "HLA-A / B / C KO" indicates the results of megakaryocytes subjected to knockout treatment of HLA-A gene, HLA-B gene, and HLA-C gene. In addition, "stained" indicates the results of staining with FITC-labeled anti-HLA-A / B / C antibody, and "unstained" indicates the results of not staining. In addition, "day 3" indicates the results of measurement 3 days after the start of culture, and "day 6" indicates the results of measurement 6 days after the start of culture.
[0136] The results showed that in megakaryocytes that had been knocked out of the HLA-A / B / C gene, 24.0% (after 3 days) and 19.7% (after 6 days) of the entire cell population became negative for HLA-A protein, HLA-B protein, and HLA-C protein (hereinafter sometimes referred to as "HLA-A / B / C protein"). This result indicates that the method of this experimental example can efficiently implement genome editing in megakaryocytes.
[0137] [Experimental Example 2]
[0138] (B2M gene knockout in megakaryocytes)
[0139] Cas9 protein and sgRNA were introduced into megakaryocytes to knock out the B2M gene. In addition, for comparison, HLA-A / B / C gene knockout was also performed. As megakaryocytes, the same immortalized human megakaryocyte line (imMKCL) as in Experimental Example 1 was used.
[0140] As Cas9 protein, a commercially available product (product name “TrueCut TM Cas9 Protein v2”, catalog number “A36498”, Thermo Fisher Scientific).
[0141] As sgRNA, a synthetic sgRNA targeting the B2M gene ("B2M-ex1g2", the target base sequence is shown in sequence number 8), a synthetic sgRNA targeting the HLA-A gene ("HLA-A-ex3g1", the target base sequence is shown in sequence number 5), a synthetic sgRNA targeting the HLA-B gene ("HLA-B-ex2g1", the target base sequence is shown in sequence number 6), and a synthetic sgRNA targeting the HLA-C gene ("HLA-C12:02-ex3g1", the target base sequence is shown in sequence number 7) were used.
[0142] In the knockout of B2M gene, 5 μg of Cas9 protein and 1.25 μg of B2M-ex1g2 were mixed and introduced into 3×10 5In the knockout of HLA-A / B / C genes, 15 μg of Cas9 protein, 1.25 μg of HLA-A-ex3g1, 1.25 μg of HLA-B-ex2g1, and 1.25 μg of HLA-C12:02-ex3g1 were mixed and introduced into 3×10 5 MaxCyte STX (MaxCyte) was used for electroporation.
[0143] The electroporated megakaryocytes were added to the culture medium of the composition shown in Table 1 above and cultured under the culture conditions of 37°C and 5% CO2. Megakaryocytes were recovered 6 days after the start of culture and stained with FITC-labeled anti-HLA-A / B / C antibody (catalog number "555552", BD Biosciences). Then, flow cytometry analysis was performed using FACS Verse (BD Biosciences) to determine the proportion of cell populations in which all HLA-A / B / C genes were knocked out.
[0144] Figure 2 It is a figure which shows the result of flow cytometry analysis. Figure 2 In the table, "wild type" indicates the results of wild type megakaryocytes, "B2M KO" indicates the results of B2M gene knockout megakaryocytes, and "HLA-A / B / C KO" indicates the results of HLA-A gene, HLA-B gene, and HLA-C gene knockout megakaryocytes. In addition, "unstained" indicates the results of not staining with FITC-labeled anti-HLA-A / B / C antibody.
[0145] The results showed that in megakaryocytes that underwent knockout of the B2M gene, 48.9% of the cell population as a whole became HLA-A / B / C protein negative. In addition, it was found that in megakaryocytes that underwent knockout of the HLA-A / B / C gene, 59.5% of the cell population as a whole became HLA-A / B / C protein negative. This result further supports that the method of this experimental example can be used to efficiently implement genome editing in megakaryocytes.
[0146] [Experimental Example 3]
[0147] (Subclone of HLA-A / B / C gene knockout megakaryocytes)
[0148] A subcloning method based on colony formation was performed to purify megakaryocytes subjected to HLA-A / B / C gene knockout treatment in Experimental Example 1. As a medium for subcloning, a medium having a composition shown in Table 2 below was used.
[0149] [Table 2]
[0150]
[0151] The megakaryocytes subjected to the knockout treatment of the HLA-A / B / C gene in Experimental Example 1 were added to the medium with the composition shown in Table 2 above, stirred, and seeded in a 100 mm culture dish. The seeding cell number was adjusted to 5×10 4 Then, the cells were cultured at 37°C and 5% CO2 for 8 to 12 days.
[0152] Next, single colonies were collected under microscopic observation and seeded into each well of a 96-well plate into which 200 μL of a medium having a composition shown in Table 1 was dispensed, and cultured at 37° C. and 5% CO 2 for 3 to 7 days.
[0153] Next, the proliferating megakaryocytes were collected and stained with FITC-labeled anti-HLA-A / B / C antibody (catalog number "555552", BD Biosciences), and then flow cytometry analysis was performed using FACS Verse (BD Biosciences).
[0154] First, if Figure 3 As shown in (a), wild-type megakaryocytes (wild-type) were used to perform flow cytometric analysis on cells not stained and cells stained with anti-HLA-A / B / C antibodies, and gating of the HLA-A / B / C protein-negative cell population was performed. Figure 3 In (a), "stained" indicates the result of staining with FITC-labeled anti-HLA-A / B / C antibody, and "unstained" indicates the result of not staining. In addition, the ellipse in the figure indicates the gate for defining the HLA-A / B / C protein negative cell population.
[0155] Next, using the above-described gating settings, the expression of HLA-A / B / C proteins in megakaryocytes cloned by subcloning was evaluated. Figure 3 (b) is a graph showing the results of flow cytometric analysis of each megakaryocyte clone. Figure 3 In (b), the image enclosed by a bold line shows an HLA-A / B / C protein-negative megakaryocyte clone.
[0156] As a result, if Figure 3 As shown in (b), 13 clones out of 71 clones were found to be HLA-A / B / C protein negative. This result showed that megakaryocyte cell lines necessary for the production of HLA-A / B / C protein-deficient platelet preparations can be prepared.
[0157] [Experimental Example 4]
[0158] (Platelets produced by HLA null megakaryocytes)
[0159] The HLA-A / B / C gene of the immortalized human megakaryocyte line (imMKCL) was knocked out in the same manner as in Experimental Example 1, and HLA-A / B / C protein-negative megakaryocytes (hereinafter sometimes referred to as "HLA null megakaryocytes") were sorted and recovered using FACSAria (BD Biosciences).
[0160] Next, the recovered megakaryocytes were washed and cultured in a medium without doxycycline, thereby releasing the forced expression of the BMI1 gene, c-MYC gene, and BCL-xL gene. Specifically, wild-type megakaryocytes and HLA null megakaryocytes were cultured at 1×10 5 The cells were seeded at a cell density of 100 / mL in an E125 flask (catalog number "431143", Corning Incorporated) at 25 mL / flask in a medium having the composition shown in Table 3 below, and cultured with shaking at 100 rpm under the conditions of 37°C and 5% CO2. As a result, platelet production was induced by megakaryocytes.
[0161] [Table 3]
[0162]
[0163] After 6 days of culture, part of the cell suspension was taken and stained with APC-labeled anti-CD41 antibody (product catalog number "303710", Bioregenerative Devices), PE-labeled anti-CD42b antibody (product catalog number "303906", Bioregenerative Devices) and FITC-labeled anti-HLA-A / B / C antibody (product catalog number "555552", BD Biosciences) for 30 minutes.
[0164] Next, flow cytometry analysis was performed using FACS Verse (BD Biosciences) to examine the expression of HLA-A / B / C proteins in platelets (CD41 / CD42b double-positive cells).
[0165] Figure 4 (a) and (b) are graphs showing the results of flow cytometry analysis. Figure 4 As shown in (a), first, a gate is set on the microcell population based on the forward scattered light signal (FSC) / side scattered light signal (SSC), and then a gate is set on the CD41 positive fraction.
[0166] Then, if Figure 4 As shown in (b), among the gated fractions, CD42b-positive fractions were defined as platelets, and the expression of HLA-A / B / C proteins was examined. Figure 4In (b), "wild type" indicates the results of platelets derived from wild type megakaryocytes, and "HLA-A / B / C KO" indicates the results of platelets derived from HLA null megakaryocytes. In addition, "stained" indicates the results of staining with FITC-labeled anti-HLA-A / B / C antibody, and "unstained" indicates the results of not staining.
[0167] The results showed that wild-type megakaryocyte-derived platelets were positive for the expression of HLA-A / B / C proteins, whereas HLA-null megakaryocyte-derived platelets were negative for the expression of HLA-A / B / C proteins.
[0168] [Experimental Example 5]
[0169] (Study on genome editing efficiency of megakaryocytes)
[0170] The B2M gene was knocked out by introducing Cas9 protein and gRNA into megakaryocytes by various methods to study the genome editing efficiency. As megakaryocytes, the same immortalized human megakaryocyte line (imMKCL) as in Experimental Example 1 was used.
[0171] Table 4 below shows the conditions for introducing the studied Cas9 protein and gRNA. The Cas9 protein was used in the form of a Cas9 expression plasmid or a Cas9 protein. As a Cas9 expression plasmid, pHL-EF1a-SphcCas9-iC-A was used. pHL-EF1a-SphcCas9-iC-A was prepared by cloning the SphcCas9 cDNA of pHL-EF1a-SphcCas9-iP-A described in Li HL, et al., Precise Correction of the DystrophinGene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9, Stem Cell Reports, 4, 143-154, 2015. into the pHL-EF1a-GW-iC-A vector.
[0172] As Cas9 protein, a commercially available product (product name “TrueCut TM Cas9 Protein v2”, catalog number “A36498”, Thermo Fisher Scientific).
[0173] gRNA is used in the form of an expression plasmid of gRNA targeting the B2M gene or in the form of sgRNA. As an expression plasmid of gRNA targeting the B2M gene, pHL-H1-B2M-sgRNA-mEF1a-RiH was used (see Suzuki D., et al., iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity, Stem Cell Reports, 14, 49-59, 2020).
[0174] As sgRNA, a synthetic sgRNA targeting the B2M gene ("B2M-ex1g2", the target base sequence is shown in SEQ ID NO: 8) was used.
[0175] In addition, the cases where the Cas9 protein and gRNA were incubated for 5 minutes before introduction into the cells to form a complex and the cases where no complex was formed were studied.
[0176] As methods for introducing Cas9 protein and gRNA, lipofectamine transfection and electroporation were studied. For lipofectamine transfection, Lipofectamine 2000 (Thermo Fisher Scientific) and Lipofectamine CRISPRMAX (Thermo Fisher Scientific) suitable for protein introduction were used. For electroporation, 4D-Nucleofector was used. TM (Lonza Co., Ltd.) and Amaxa TM P4Primary Cell 4D-Nucleofector TM X KitS (LONZA CO., LTD.).
[0177] [Table 4]
[0178]
[0179] Megakaryocytes after introduction of Cas9 protein and gRNA were cultured in a culture medium with the composition shown in the above Table 1 under the culture conditions of 37°C and 5% CO2.
[0180] Four days and seven days after the introduction of Cas9 protein and gRNA, each megakaryocyte was stained with FITC-labeled anti-HLA-A / B / C antibody (catalog number "555552", BD Biosciences). In addition, the same cells were stained with propidium iodide (PI). Next, flow cytometry analysis was performed using FACS Verse (BD Biosciences) to evaluate the proportion of megakaryocytes in which the B2M gene was knocked out. In addition, dead cells were detected by analyzing the proportion of PI-positive cells to evaluate cell damage.
[0181] Figure 5 (a) and (b), Figure 6 (a) and (b) show the analysis results 4 days after the introduction of Cas9 protein and gRNA.
[0182] Figure 5 (a) shows the results of the control group without the introduction of Cas9 protein and gRNA. Figure 5 In (a), "stained" indicates the result of staining with FITC-labeled anti-HLA-A / B / C antibody, and "unstained" indicates the result of not staining.
[0183] Figure 5 (b) shows the results of the group in which Cas9 protein and gRNA were introduced using Lipofectamine 2000. Figure 5 In (b), "plasmid vector" indicates the result of introducing Cas9 protein and gRNA in the form of expression plasmid, "RNP separation" indicates the result of no complex of Cas9 protein and gRNA formed, and "RNP pre-mix" indicates the result of forming a complex after mixing Cas9 protein and gRNA and incubating them.
[0184] Figure 5 In (a) and (b), "SSC" indicates the side scattered light signal, and "anti-HLA-ABC" indicates the staining intensity of the anti-HLA-A / B / C antibody labeled with FITC.
[0185] Figure 6 (a) shows the results of the group in which Cas9 protein and gRNA were introduced using Lipofectamine CRISPRMAX. Figure 6 (b) shows the results of the group into which Cas9 protein and gRNA were introduced by electroporation.
[0186] Figure 6In (a) and (b), "plasmid vector" indicates the result of introducing Cas9 protein and gRNA in the form of expression plasmid, "RNP separation" indicates the result of not forming a complex of Cas9 protein and gRNA, and "RNP premix" indicates the result of forming a complex after mixing Cas9 protein and gRNA and incubating. In addition, "SSC" indicates the side scattered light signal, and "anti-HLA-ABC" indicates the staining intensity of anti-HLA-A / B / C antibody labeled with FITC.
[0187] Figure 7 (a) and (b), Figure 8 (a) and (b) are diagrams showing the analysis results 7 days after the introduction of Cas9 protein and gRNA.
[0188] Figure 7 (a) shows the results of the control group without the introduction of Cas9 protein and gRNA. Figure 7 In (a), "stained" indicates the result of staining with FITC-labeled anti-HLA-A / B / C antibody, and "unstained" indicates the result of not staining.
[0189] Figure 7 (b) shows the results of the group in which Cas9 protein and gRNA were introduced using Lipofectamine 2000. Figure 7 In (b), "plasmid vector" indicates the result of introducing Cas9 protein and gRNA in the form of expression plasmid, "RNP separation" indicates the result of no complex of Cas9 protein and gRNA formed, and "RNP premix" indicates the result of forming a complex after mixing Cas9 protein and gRNA and incubating them.
[0190] Figure 7 In (a) and (b), "SSC" indicates the side scattered light signal, and "anti-HLA-ABC" indicates the staining intensity of the anti-HLA-A / B / C antibody labeled with FITC.
[0191] Figure 8 (a) shows the results of the group in which Cas9 protein and gRNA were introduced using Lipofectamine CRISPRMAX. Figure 8 (b) shows the results of the group into which Cas9 protein and gRNA were introduced by electroporation.
[0192] Figure 8In (a) and (b), "plasmid vector" indicates the result of introducing Cas9 protein and gRNA in the form of expression plasmid, "RNP separation" indicates the result of not forming a complex of Cas9 protein and gRNA, and "RNP premix" indicates the result of forming a complex after mixing Cas9 protein and gRNA and incubating. In addition, "SSC" indicates the side scattered light signal, and "anti-HLA-ABC" indicates the staining intensity of anti-HLA-A / B / C antibody labeled with FITC.
[0193] As a result, in the analysis using the expression plasmid vector of Cas9 and gRNA, almost no genome editing was observed in the case of liposome transfection (0.0% or 0.1%, Figure 5 (b) Figure 6 (a) Figure 7 (b) Figure 8 (a) "plasmid vector"), and in the case of electroporation, it can be weakly observed (3.0% ( Figure 6 (b)) and 4.6% ( Figure 8 (b)) "Plasmid vector"). Thus, the difficulty of introducing genes (plasmid DNA) into megakaryocytes was confirmed again.
[0194] Then, in the analysis using Cas9 protein and gRNA, the genome editing efficiency was very low (less than 0.5%, Figure 5 (b) and Figure 7 (b) "RNP separation" and "RNP premixing"). This result is considered to be due to the fact that Lipofectamine 2000 is not a reagent suitable for the introduction of Cas9 protein or sgRNA.
[0195] In contrast, when using a liposome transfection reagent for protein introduction (Lipofectamine CRISPRMAX), the genome editing efficiency was 0.1% (after 4 days) and 0.0% (after 7 days) when there was no incubation, but increased to 2.1% (after 4 days) and 3.5% (after 7 days) when there was incubation ( Figure 6 (a) and Figure 8 (a)). Furthermore, when electroporation was used, the genome editing efficiency increased from 2.8% (without incubation) to 45.3% (with incubation) after 4 days, depending on the presence or absence of incubation ( Figure 6 (b)), the genome editing efficiency increased from 2.4% (without incubation) to 51.9% (with incubation) after 7 days ( Figure 8 (b)), a significant increase.
[0196] Therefore, it can be seen that when Cas family proteins and gRNA are introduced into megakaryocytes for genome editing, in any of the methods suitable for protein introduction, liposome transfection and electroporation, when the complex of Cas family proteins and gRNA is formed and introduced, the genome editing efficiency is greatly increased (increased by one order of magnitude). In particular, the genome editing efficiency obtained when the above-mentioned complex is introduced using electroporation is very high, and there is no report on the example of genome editing at such a high efficiency in megakaryocytes.
[0197] It should be noted that in the analysis results of PI staining, when Cas9 protein and gRNA were introduced by any method of liposome transfection and electroporation, regardless of whether a complex was formed, the proportion of cells stained with PI was low to the same extent (4.3% or less after 4 days and 1.5% or less after 7 days). Therefore, it can be seen that the method of introducing a complex of Cas family proteins and gRNA into megakaryocytes for genome editing is also sufficiently low in damage (cytotoxicity) to megakaryocytes.
[0198] Industrial Applicability
[0199] According to the present invention, a technology for producing genetically modified megakaryocytes and modified platelets can be provided. Sequence Listing <110> Otsuka Pharmaceutical Co., Ltd. National University Corporation Kyoto University <120> Genetically modified megakaryocytes, modified platelets and methods for producing the same <130> PC-31709 <150> JP2020-034255 <151> 2020-02-28 <160> 8 <170> PatentIn version 3.5 <210> 1 <211> 20 <212> RNA <213> Artificial sequence <220> <223> Synthetic spacer sequence <220> <221> misc_feature <222> (1)..(20) <223> n is a, c, g or u <400> 1 nnnnnnnnnn nnnnnnnnnn 20 <210> 2 <211> 103 <212> RNA <213> Artificial sequence <220> <223> Synthetic sgRNA <220> <221> misc_feature <222> (1)..(20) <223> n is a, c, g or u <400> 2 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60 cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu uuu 103 <210> 3 <211> 42 <212> RNA <213> Artificial sequence <220> <223> Synthetic crRNA <220> <221> misc_feature <222> (1)..(20) <223> n is a, c, g or u <400> 3 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcuguuu ug 42 <210> 4 <211> 70 <212> RNA <213> Artificial sequence <220> <223> Synthetic tracrRNA <400> 4 caaaacagca uagcaaguua aaauaaggcu aguccguuau caacuugaaa aaguggcacc 60 gagucggugc 70 <210> 5 <211> 23 <212> DNA <213> Man(Homo sapiens) <400> 5 ggacctgcgc tcttggaccg cgg 23 <210> 6 <211> 23 <212> DNA <213> Man(Homo sapiens) <400> 6 gctgtcgaac ctcacgaact ggg <210> 7 <211> 23 <212> DNA <213> Man(Homo sapiens) <400> 7 ggccgagatg tctcgctccg tgg <210> 8 <211> 23 <212> DNA <213> Man(Homo sapiens) <400> 8 gagtagcgcg together agg
Claims
1. A method for producing genetically modified megakaryocytes, comprising the steps of introducing CRISPR-associated (Cas) family proteins and guide RNA (gRNA) into megakaryocytes to modify target genes, In the step, the Cas family protein to be introduced into the megakaryocyte and the gRNA are preliminarily incubated to form a complex, The introduction of the Cas family protein and the gRNA is carried out by electroporation.
2. The manufacturing method according to claim 1, wherein: The target gene is (i) human leukocyte antigen (HLA)-A, HLA-B and HLA-C gene, or (ii) β2-microglobulin (B2M) gene, and the modification is the disruption of the target gene.
3. The manufacturing method according to claim 1 or 2, wherein: The megakaryocytes are megakaryocytes obtained by differentiating pluripotent stem cells.
4. A method for producing modified platelets, comprising: A step of introducing Cas family proteins and gRNA into megakaryocytes to modify target genes, thereby obtaining genetically modified megakaryocytes; and a step of producing platelets from the genetically modified megakaryocytes to obtain modified platelets, In the step of obtaining the genetically modified megakaryocytes, the Cas family protein to be introduced into the megakaryocytes is preliminarily incubated with the gRNA to form a complex, The introduction of the Cas family protein and the gRNA is carried out by electroporation.
5. The manufacturing method according to claim 4, wherein: The target gene is (i) HLA-A, HLA-B and HLA-C gene, or (ii) B2M gene, and the modification is the disruption of the target gene.
6. The manufacturing method according to claim 4 or 5, wherein: The megakaryocytes are megakaryocytes obtained by differentiating pluripotent stem cells.
